Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://otc.duke.edu/wp-content/uploads/2022/08/4722019_Beasley_SITC_2020_poster_FINAL_2020-10-28.jpg

Istari Oncology Presents Positive Data from Phase 1 Study

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Data suggest that PVSRIPO, either…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/precision-springworks-partnership-1.jpg

Precision and SpringWorks Announce Clinical Collaboration

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/woman-massaging-her-foot-during-sport-practice-P3DZ7ZK.jpg

Newly published data shows positive results in KRYSTEXXA trial

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate — Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/vaccination-is-important-for-immunization-P7JTW65-1.jpg

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies

Sept. 1, 2020 12:05 UTC Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM ~25-35 % survival over 5 years from diagnosis in vaccinated…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/GridTherapeuticLogo-e1501067523319.png

Grid Therapeutics Announces Enrollment of 1st Patient in Phase 1 Study

Grid Therapeutics, LLC, a clinical-stage biotechnology company developing a first-in-class, novel, human-derived targeted immunotherapy for solid tumors, today announced that the first patient has been dosed in a Phase 1/2 study of GT103 in patients with…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/close-up-on-vaccine-and-medical-syringe-Q8V7CBC-1.jpg

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial

June 8, 2020 at 7:00 AM EDT PDF Version -PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic – -PBCAR269A…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/precision_revised_logo_1_color.png

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A

Precision BioSciences, Inc. (DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced the initiation of patient dosing in a Phase 1/2a clinical trial…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Polarean.png

Polarean Imaging plc Announces Positive Results From Pivotal Phase III Clinical Trials

Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, today announced positive top-line results from two pivotal Phase III clinical trials of the…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/precision_revised_logo_1_color.png

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced updated interim clinical data from the ongoing Phase 1 trial of its…

Read More